Regulus Therapeutics Inc. (RGLS)
- Previous Close
2.6900 - Open
2.8300 - Bid 2.6100 x 100
- Ask 2.6700 x 500
- Day's Range
2.6400 - 2.8300 - 52 Week Range
1.0800 - 3.7900 - Volume
403,616 - Avg. Volume
3,145,730 - Market Cap (intraday)
176.102M - Beta (5Y Monthly) 1.55
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5800 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.20
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
www.regulusrx.comRecent News: RGLS
Performance Overview: RGLS
Trailing total returns as of 5/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RGLS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RGLS
Valuation Measures
Market Cap
173.48M
Enterprise Value
152.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
8.19
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-5.21
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-50.20%
Return on Equity (ttm)
-110.27%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-30.04M
Diluted EPS (ttm)
-1.5800
Balance Sheet and Cash Flow
Total Cash (mrq)
23.77M
Total Debt/Equity (mrq)
14.64%
Levered Free Cash Flow (ttm)
-16.93M